Loading organizations...
Constellation Pharmaceuticals is a Cambridge, Massachusetts-based biopharmaceutical company that develops epigenetic drugs targeting histone modification for the treatment of oncology, autoimmune, inflammatory, and neurological diseases. Operating as a venture-backed biotechnology enterprise under the early leadership of executives like Mark A. Goldsmith, the firm advances preclinical drug candidates through its proprietary technology platform and secured $32 million in Series A funding to support its initial clinical research efforts. The company's financial backing and strategic corporate development have been supported by prominent healthcare and life sciences investors, including Third Rock Ventures, The Column Group, and Venrock. After navigating various complex corporate development phases, which included the conclusion of major research collaborations and previously lapsed acquisition options, the clinical-stage enterprise was ultimately acquired by a larger entity. Constellation Pharmaceuticals was founded in 2008 by researchers Danny Reinberg, David Allis, and Yang Shi.
Constellation Pharmaceuticals has raised $490.0M across 10 funding rounds.
Constellation Pharmaceuticals has raised $490.0M in total across 10 funding rounds.
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company, not a technology company in the traditional software or hardware sense, specializing in epigenetics-based therapies for cancer.[1][2][3] It develops small-molecule drugs that modulate gene expression in tumor and immune cells to treat serious unmet needs, particularly in hematologic malignancies like myelofibrosis.[1][2] Key products include pelabresib (CPI-0610, BET inhibitor) in Phase 3 trials for primary myelofibrosis combined with ruxolitinib, CPI-0209 (EZH2 inhibitor) in Phase 1/2 for advanced solid tumors and malignancies, and earlier-stage candidates like CPI-1205 and CPI-482.[1][2][3] The company serves cancer patients facing drug resistance and abnormal gene expression, solving problems rooted in epigenetic modifications that drive disease progression.[2][3] As of 2021, it operated as a subsidiary of MorphoSys US Inc., with later involvement from Novartis via MorphoSys acquisition in 2024, though growth has involved corporate challenges like ended partnerships.[3][5][7]
Founded in 2008 in Cambridge, Massachusetts (initially as Epigenetix, Inc., renamed Constellation Pharmaceuticals in March 2008), the company emerged from expertise in epigenetics.[1][3] Key founders Danny Reinberg, David Allis, and Yang Shi—renowned scientists in chromatin biology and gene regulation—built it around an epigenetics platform to target cancer via small molecules.[1] Early traction included deals with big pharma, such as a collaboration that later ended, and an acquisition option that lapsed amid capital market difficulties.[5] Pivotal moments involved rebooting under new CEO Jigar Raythatha, focusing on advancing pelabresib and CPI-0209 while navigating independence or partnerships.[5] By 2021, it became a MorphoSys subsidiary; MorphoSys was acquired by Novartis in July 2024.[3][7]
Constellation rides the epigenetics revolution in oncology, where aberrant gene regulation via chromatin modifications fuels ~50% of cancers, aligning with trends in precision medicine and immunotherapy combinations.[1][2] Timing is ideal amid rising myelofibrosis cases and demand for next-gen therapies post-JAK inhibitors like ruxolitinib, with market forces favoring modalities tackling resistance.[3] As a biotech innovator, it influences the ecosystem by validating epigenetic targets, inspiring similar platforms, and contributing to M&A dynamics—exemplified by its MorphoSys integration and Novartis orbit, accelerating clinical translation.[5][7]
Constellation's path forward hinges on pelabresib readout in myelofibrosis trials and CPI-0209 expansion, potentially unlocking approvals and partnerships under Novartis/MorphoSys stewardship.[2][7] Trends like AI-driven target discovery and combo regimens will shape it, evolving its role from standalone innovator to integrated pipeline asset in big pharma's oncology push. Watch for monotherapy pivots or broader epigenetic applications, tying back to its founding vision of transforming cancer epigenomes into treatable targets.[1][5]
Constellation Pharmaceuticals has raised $490.0M across 10 funding rounds. Most recently, it raised $100.0M Other Equity in April 2018.
Constellation Pharmaceuticals has raised $490.0M in total across 10 funding rounds.
Constellation Pharmaceuticals's investors include Casdin Capital, Cormorant Asset Management, Deerfield Management, Fidelity Management & Research Company, Hillhouse Capital, NS Investment, OrbiMed, Sirona Capital, SR One, The Column Group, Third Rock Ventures, Topspin Partners.
